Conference Reports for NATAP

Back

HIV Glasgow 28-31 October 2018     Week 48 Resistance Analyses of the Once-daily, Single-tablet Regimen Darunavir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the AMBER and EMERALD Phase 3 Trials - (02/6/19)   Comorbidities, Comedication, and Polypharmacy Burden in Patients With HIV: Retrospective Claims Data in Germany - (01/28/19)   HIV and Cancer Curative Approaches Cross-disciplinary research - (11/09/18)   Pharmacokinetics of MK-8591, Dolutegravir and Tenofovir Disoproxil Fumarate Are Not Altered After Coadministration When Compared to Single Agent Administration - (11/09/18)   Factors associated with HIV associated neurocognitive disorder in an unselected cohort in East and South London-The HAND study - (11/08/18)   Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1992: predictive factors associated with more than 25 years of survival - (11/08/18)   HIV and Ageing Challenges and Goals - Plenary Talk at Glasgow 2018 - (11/08/18)   Cumulative Safety Review of Elvitegravir and Bictegravir use During Pregnancy and Risk of Neural Tube Defects - (11/08/18)   High Prevalence of Previously Undocumented Baseline M184V/I Does Not Affect Virologic Outcome in Virologically-Suppressed Patients Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from a Boosted Protease Inhibitor-based Regimen - (11/08/18)   ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV - (11/08/18)   Analysis of Patients Completing the Ibalizumab Phase 3 Trial and Expanded Access Program - (11/07/18)   E-Vaccine Registry Helps HIV Group Improve Poor Vaccination Record - Mark Mascolini (11/07/18)   SVR With DAAs--and Darunavir--Tied to Lipid Jumps in Big HCV/HIV Group - Mark Mascolini (11/07/18)   Viral Load and Genotypic Resistance Score Predict Response to 2-Drug ART Switch - Mark Mascolini (11/07/18)   Two Thirds Reach Sub-50 Viral Load Through 48 Weeks With Ibalizumab - Mark Mascolini (11/07/18)   HIV Linked to Higher Odds of Anemia, Neutropenia, and Thrombocytopenia - Mark Mascolini (11/07/18)   Waist-to-Hip Ratio Predicts Hepatic Steatosis in People With HIV - Mark Mascolini (11/07/18)   Viral Load and Genotypic Resistance Score Predict Response to 2-Drug ART Switch - Mark Mascolini (11/07/18)   Approaches towards a cure for HIV - (11/05/18)   Meta-analysis of the risk of Grade 3/4 or serious clinical adverse events in 12 randomised trials of PrEP - Mark Mascolini - (11/05/18)   How safe is PrEP? An analysis of the safety of TDF(/FTC) as PrEP - (11/05/18)   Prevalence of mental health problems among people living with HIV: - (11/05/18)   Dolutegravir- versus an efavirenz 400mg-based regimen for the initial treatment of HIV-infected patients in Cameroon: 48-week efficacy results of the NAMSAL ANRS 12313 trial - (11/05/18)   Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 100 Results From the SWORD-1 and SWORD-2 Studies - (11/05/18)   Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG + 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG + TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: Subgroup Analyses in the GEMINI Studies - (11/05/18)   Comparison of Viral Replication Below 50 c/mL for Two-Drug (DTG + RPV) Versus Three-Drug Current Antiretroviral Regimen (CAR) Therapy in the SWORD-1 and SWORD-2 Studies - (11/05/18)   Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 48 Subgroup Analysis in Randomised Cohort Participants - (11/05/18)   Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - (11/05/18)   Safety, Efficacy and Durability of Long-acting Cabotegravir (CAB) and Rilpivirine (RPV) as Two-Drug IM Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 160 Results - (11/05/18)   B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naïve adults with high baseline viral load or low baseline CD4 count in two phase III randomized, controlled clinical trials: week 96 results - Mark Mascolini (11/02/18)   Distribution in Cerebrospinal Fluid (CSF) of Cabotegravir (CAB) and Rilpivirine (RPV) After Intramuscular Administration of Long-Acting (LA) Injectable Suspensions in HIV-1-Infected Patients - oral talk has extra data - (11/02/18)   Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study - (11/02/18)   Impact of HIV on quality of life: Preliminary data exploring differences by sex and country (UK and US) using the HIV Dependent Quality of Life questionnaire (HIVDQoL) - (11/02/18)   New Drugs and Strategies for the Treatment of HIV - (11/02/18)   Safety and Efficacy of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1 Infected Adults With Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations - (11/02/18)   The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients - (11/02/18)   Comparison of HIV-1 Intermittent Viremia for Two Drug (DTG+RPV) vs Three Drug Current Antiretroviral Therapy in the SWORD-1 and SWORD-2 Studies - (11/02/18)   Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Participants (BRIGHTE Study) - (11/02/18)   Patient Proportion With Above-Target LDL Rises 70% With TDF-to-TAF Switch - Mark Mascolini - (11/01/18)   OUTCOMES OF PATIENTS NOT ACHIEVING PRIMARY ENDPOINT FROM AN IBALIZUMAB PHASE 3 TRIAL - Mark Mascolini - (11/01/18)   Phase III Randomized, Controlled Clinical Trial of Bictegravir Coformulated with FTC/TAF in a Fixed-dose Combination (B/F/TAF) versus Dolutegravir (DTG) + F/TAF in Treatment-naïve HIV-1 Positive Adults: Week 96 - Mark Mascolini - (11/01/18)   Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA® in Treatment-Naïve Adults with HIV-1 - Mark Mascolini - (11/01/18)   Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy - (11/01/18)   ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen - (11/01/18)   ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen - (11/01/18)   Good HIV Response Rate, Sustained Safety Through 96 Weeks With D/C/F/TAF - Mark Mascolini - (10/30/18)   Efficacy of MK-8591 against diverse HIV-1 subtypes and NRTI-resistant clinical isolates - (10/30/18)   Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates - (10/30/18)   Viral Decay Similar With 2- and 3-Drug Dolutegravir Regimens - Mark Mascolini - (10/30/18)   Good Later Responses in Some People Whose Ibalizumab "Failed" After 7 Days - Mark Mascolini - (10/30/18)   Higher Hospital Rate With HIV in Women and Straight Men Than in MSM - Mark Mascolini - (10/30/18)   No Uptick in HIV Replication After Switch to DTG/3TC in Randomized Trial - Mark Mascolini - (10/29/18)   Mixed Signals With Cardiovascular Markers in Dolutegravir Switch Study - Mark Mascolini - (10/29/18)   Neuro Impairment in Over One Third of London HIV Group--Anxiety Doubles Risk - Mark Mascolini - (10/29/18)   TDF/FTC PrEP as Safe as Placebo in Meta-analysis of 13 Trials Across Globe - Mark Mascolini - (10/29/18)   Higher Hospital Rate With HIV in Women and Straight Men Than in MSM - Mark Mascolini (10/29/18)   Annual Comorbidity Cost Averages $8674 in German Analysis of People With HIV - Mark Mascolini (10/29/18)   The economic burden of comorbidities among people living with HIV in Germany; A cohort analysis using health insurance claims data - (10/29/18)   Multimorbidity and risk of death differs by gender in people living with HIV in the Netherlands - the ATHENA cohort study - (10/29/18)   Non-HIV Comorbidity Predicts Mortality: Impact Greater in Women - Mark Mascolini - (10/29/18)   Integrase Inhibitors, Once-Daily Dosing Boost First-ART Response in 77,999-Person Analysis - Mark Mascolini (10/29/18)   Integrase Inhibitor Use Doubles in Big Elderly Cohort--No Jump in 2-Drug Regimens / Use of 2-Drug ART - Mark Mascolini (10/29/18)   Polypharmacy in One Third of Big HIV Cohort vs One Fifth of Non-HIV Group - Mark Mascolini (10/29/18)   ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen - (10/29/18)